{"id":"s-c-injection","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"5-10%","effect":"Hypothyroidism"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"30-40%","effect":"Nausea"},{"rate":"40-50%","effect":"Cough"},{"rate":"50-60%","effect":"Pruritus"},{"rate":"60-70%","effect":"Rash"},{"rate":"70-80%","effect":"Hypertension"},{"rate":"80-90%","effect":"Decreased appetite"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, it prevents the interaction with its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation. This leads to an enhanced anti-tumor immune response.","oneSentence":"This drug targets the PD-1 receptor to modulate the immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:59.695Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT07485764","phase":"PHASE4","title":"Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-06","conditions":"Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis","enrollment":186},{"nctId":"NCT05722522","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-08-10","conditions":"Rotator Cuff Tendinopathy","enrollment":33},{"nctId":"NCT04563923","phase":"PHASE2","title":"Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2020-10-10","conditions":"Bullous Pemphigoid","enrollment":15},{"nctId":"NCT04083781","phase":"PHASE3","title":"Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-10-21","conditions":"Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":134},{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT04717635","phase":"PHASE3","title":"Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-03-30","conditions":"Adult Onset Still's Disease","enrollment":14},{"nctId":"NCT05985915","phase":"PHASE3","title":"A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-27","conditions":"Sjogrens Syndrome","enrollment":612},{"nctId":"NCT06577766","phase":"PHASE1","title":"A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-09-03","conditions":"Obesity, Overweight","enrollment":63},{"nctId":"NCT05397496","phase":"PHASE1","title":"Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-10-03","conditions":"B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)","enrollment":61},{"nctId":"NCT04648930","phase":"","title":"Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-27","conditions":"Allergic Rhinitis","enrollment":50},{"nctId":"NCT06409130","phase":"PHASE2","title":"Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-20","conditions":"Alcohol-related Liver Disease","enrollment":270},{"nctId":"NCT05649137","phase":"PHASE3","title":"A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-04","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":512},{"nctId":"NCT06717698","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Chronic Kidney Disease","enrollment":465},{"nctId":"NCT06927310","phase":"PHASE3","title":"The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2025-04-28","conditions":"Idiopathic Short Stature","enrollment":300},{"nctId":"NCT06470048","phase":"PHASE2","title":"A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-09","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":200},{"nctId":"NCT05636176","phase":"PHASE3","title":"A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2023-05-08","conditions":"Heart Failure","enrollment":5600},{"nctId":"NCT06868212","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-11","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":400},{"nctId":"NCT04638647","phase":"PHASE4","title":"Secukinumab Open Label Roll-over Extension Protocol","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-22","conditions":"Autoimmunity, Inflammation","enrollment":1000},{"nctId":"NCT03811561","phase":"PHASE3","title":"A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-05-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1500},{"nctId":"NCT07102628","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-10-03","conditions":"Acute Coronary Syndrome","enrollment":300},{"nctId":"NCT07309562","phase":"PHASE3","title":"The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2026-01-20","conditions":"Small for Gestational Age","enrollment":141},{"nctId":"NCT05380453","phase":"PHASE3","title":"Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-09-29","conditions":"Giant Cell Arteritis","enrollment":151},{"nctId":"NCT06403761","phase":"PHASE1","title":"Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-06","conditions":"Diabetes Mellitus, Type 2","enrollment":158},{"nctId":"NCT03631199","phase":"PHASE3","title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer","enrollment":673},{"nctId":"NCT05891496","phase":"PHASE3","title":"A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-06-20","conditions":"Alzheimers Disease","enrollment":23},{"nctId":"NCT07226089","phase":"PHASE3","title":"Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.","status":"RECRUITING","sponsor":"Rabin Medical Center","startDate":"2026-02","conditions":"ISS, SGA","enrollment":254},{"nctId":"NCT06597006","phase":"PHASE3","title":"Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-28","conditions":"Familial Hypercholesterolemia - Homozygous","enrollment":9},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT05248646","phase":"PHASE3","title":"Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-03-15","conditions":"Immunoglobulin A Nephropathy","enrollment":530},{"nctId":"NCT06015893","phase":"PHASE2","title":"Semaglutide Therapy for Alcohol Reduction (STAR)","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-10-17","conditions":"Addiction, Alcohol Use Disorder","enrollment":52},{"nctId":"NCT03252938","phase":"PHASE1","title":"Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2017-08-15","conditions":"Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma","enrollment":83},{"nctId":"NCT06846281","phase":"PHASE3","title":"Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-23","conditions":"Relapsing Multiple Sclerosis","enrollment":360},{"nctId":"NCT06433557","phase":"PHASE2","title":"A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Growth Disorders A/S","startDate":"2024-07-26","conditions":"Achondroplasia","enrollment":22},{"nctId":"NCT06939088","phase":"PHASE2","title":"Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder","status":"RECRUITING","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2025-05-05","conditions":"Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence","enrollment":108},{"nctId":"NCT06388187","phase":"PHASE3","title":"A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-06-24","conditions":"Obesity","enrollment":300},{"nctId":"NCT07313917","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","status":"NOT_YET_RECRUITING","sponsor":"Longbio Pharma","startDate":"2026-01-20","conditions":"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","enrollment":150},{"nctId":"NCT07136714","phase":"PHASE4","title":"Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity","status":"RECRUITING","sponsor":"Nordsjaellands Hospital","startDate":"2025-09-11","conditions":"Major Depressive Disorder","enrollment":116},{"nctId":"NCT04881825","phase":"PHASE3","title":"Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zealand Pharma","startDate":"2021-06-16","conditions":"Short Bowel Syndrome","enrollment":129},{"nctId":"NCT06644300","phase":"PHASE1","title":"Study of BM230 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Biomissile Pharmaceuticals Co., Ltd.","startDate":"2024-12-16","conditions":"Solid Tumor","enrollment":123},{"nctId":"NCT04251156","phase":"PHASE3","title":"Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-12-08","conditions":"Overweight, Obesity, Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT05462990","phase":"PHASE2","title":"A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-09","conditions":"Osteoarthritis, Knee","enrollment":101},{"nctId":"NCT06659692","phase":"PHASE1","title":"Pharmacokinetics of FSH and hCG Following Multiple Dose of Gonadotropins-IBSA.","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2024-10-10","conditions":"Ovarian Stimulation, Infertility","enrollment":28},{"nctId":"NCT06142383","phase":"PHASE2","title":"A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-12","conditions":"Heart Failure","enrollment":136},{"nctId":"NCT06781957","phase":"PHASE1","title":"Pharmacokinetics of FSH and hCG After a Single Subcutaneous Injection of Gonadotropins-IBSA","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2024-09-15","conditions":"OVARIAN STIMULATION, Infertility","enrollment":29},{"nctId":"NCT05388760","phase":"PHASE2","title":"Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"LEO Pharma","startDate":"2022-09-07","conditions":"Atopic Dermatitis","enrollment":24},{"nctId":"NCT06390501","phase":"NA","title":"The Effect of Weekly Semaglutide Treatment on Energy Expenditure","status":"COMPLETED","sponsor":"Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences","startDate":"2024-04-01","conditions":"Obesity; Drug","enrollment":60},{"nctId":"NCT06065540","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":2734},{"nctId":"NCT07355738","phase":"PHASE1","title":"Bioequivalence Study of GZR18 Injection Before and After CMC Change","status":"RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-01-09","conditions":"Obesity&T2D","enrollment":138},{"nctId":"NCT05476094","phase":"PHASE1","title":"Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects","status":"COMPLETED","sponsor":"AMIpharm Co., Ltd.","startDate":"2022-08-10","conditions":"Healthy Subjects, Submental Fat","enrollment":26},{"nctId":"NCT06780449","phase":"PHASE3","title":"A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-02-10","conditions":"Obesity","enrollment":400},{"nctId":"NCT01808599","phase":"PHASE2","title":"Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2013-12","conditions":"MALT Lymphoma","enrollment":112},{"nctId":"NCT07342803","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients","status":"RECRUITING","sponsor":"Longbio Pharma","startDate":"2025-01-25","conditions":"Allergic Asthma","enrollment":200},{"nctId":"NCT06323174","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-19","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT05579249","phase":"PHASE4","title":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-19","conditions":"Obesity","enrollment":500},{"nctId":"NCT06041217","phase":"PHASE3","title":"A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-15","conditions":"Overweight, Obesity","enrollment":242},{"nctId":"NCT05199571","phase":"PHASE4","title":"Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-22","conditions":"Relapsing Multiple Sclerosis","enrollment":99},{"nctId":"NCT05996848","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-08-15","conditions":"Obesity or Overweight","enrollment":300},{"nctId":"NCT07112339","phase":"PHASE4","title":"A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-15","conditions":"Diabetes Mellitus, Type 2","enrollment":586},{"nctId":"NCT05076422","phase":"PHASE1","title":"A Study to Test How Well Men Tolerate Different Doses of BI 3006337","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-10-18","conditions":"Healthy","enrollment":80},{"nctId":"NCT06267092","phase":"PHASE1","title":"A Study of How CagriSema Works on Appetite in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Overweight, Obesity","enrollment":164},{"nctId":"NCT07323329","phase":"PHASE2, PHASE3","title":"Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization","status":"RECRUITING","sponsor":"Beni-Suef University","startDate":"2025-10-10","conditions":"Infertility, Infertility (IVF Patients)","enrollment":165},{"nctId":"NCT05201066","phase":"PHASE2","title":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":33},{"nctId":"NCT05746806","phase":"NA","title":"Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-29","conditions":"Recurrent Prostate Cancer","enrollment":36},{"nctId":"NCT06326047","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-18","conditions":"Diabetes Mellitus, Type 2","enrollment":299},{"nctId":"NCT06275724","phase":"","title":"Specified Drug-use Survey of Leqvio for s.c. Injection.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-04","conditions":"Familial Hypercholesterolaemia, Hypercholesterolaemia","enrollment":585},{"nctId":"NCT05721989","phase":"PHASE1","title":"A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-02-03","conditions":"Healthy Participants","enrollment":267},{"nctId":"NCT07299955","phase":"PHASE1","title":"A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Biocon Biologics UK PLC","startDate":"2026-01-09","conditions":"Healthy Male Participants","enrollment":150},{"nctId":"NCT06505928","phase":"PHASE2","title":"A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2024-12-11","conditions":"Hepatitis D","enrollment":90},{"nctId":"NCT04982575","phase":"PHASE2","title":"Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-08-02","conditions":"Diabetes Mellitus, Type 2","enrollment":92},{"nctId":"NCT05499013","phase":"PHASE1, PHASE2","title":"Study to Assess SLN124 in Patients With Polycythemia Vera","status":"ACTIVE_NOT_RECRUITING","sponsor":"Silence Therapeutics plc","startDate":"2023-01-26","conditions":"Polycythemia Vera","enrollment":69},{"nctId":"NCT05758415","phase":"PHASE3","title":"Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-08-02","conditions":"Rotator Cuff Tendinopathy","enrollment":60},{"nctId":"NCT04770532","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-05","conditions":"Diabetes Mellitus, Type 2","enrollment":526},{"nctId":"NCT06534411","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-11-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1023},{"nctId":"NCT04940078","phase":"PHASE1","title":"A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-07-07","conditions":"Obesity & Overweight","enrollment":40},{"nctId":"NCT05564104","phase":"PHASE1","title":"A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-04-05","conditions":"Hepatic Impairment, Healthy Volunteers","enrollment":32},{"nctId":"NCT05486065","phase":"PHASE2","title":"A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-08","conditions":"Diabetes Mellitus, Type 2","enrollment":245},{"nctId":"NCT05646706","phase":"PHASE3","title":"A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-04","conditions":"Obesity","enrollment":1407},{"nctId":"NCT05847283","phase":"NA","title":"DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT","status":"RECRUITING","sponsor":"Tam Anh TP. Ho Chi Minh General Hospital","startDate":"2023-06-22","conditions":"Diminished Ovarian Reserve","enrollment":730},{"nctId":"NCT05878938","phase":"PHASE3","title":"A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-06-26","conditions":"Haemophilia A, Haemophilia A With Inhibitors","enrollment":61},{"nctId":"NCT06588504","phase":"PHASE1","title":"Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-09-10","conditions":"Diabetes Mellitus, Type 1","enrollment":38},{"nctId":"NCT05689372","phase":"","title":"Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-02-28","conditions":"Diabetes Mellitus, Type 2","enrollment":600},{"nctId":"NCT04460885","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-25","conditions":"Diabetes Mellitus, Type 2","enrollment":984},{"nctId":"NCT04698018","phase":"PHASE1","title":"A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-20","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT04880850","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-14","conditions":"Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT04588259","phase":"PHASE3","title":"Research Study to Compare a New Medicine \"Fast-acting Insulin Aspart\" to Another Medicine \"Insulin Aspart\" in Chinese People With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-09","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":331},{"nctId":"NCT05013229","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":679},{"nctId":"NCT06323161","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-26","conditions":"Type 2 Diabetes","enrollment":274},{"nctId":"NCT07254325","phase":"PHASE1","title":"Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","startDate":"2025-12-15","conditions":"Psoriasis","enrollment":114},{"nctId":"NCT07193147","phase":"PHASE1","title":"Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-10-20","conditions":"Diabetes","enrollment":36},{"nctId":"NCT04940065","phase":"","title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-30","conditions":"Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis","enrollment":367},{"nctId":"NCT04916470","phase":"PHASE3","title":"Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-06-15","conditions":"Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2","enrollment":617},{"nctId":"NCT07134335","phase":"PHASE2","title":"UBT251 Injection Phase II Clinical Study (CKD)","status":"RECRUITING","sponsor":"The United Bio-Technology (Hengqin) Co., Ltd.","startDate":"2025-09-01","conditions":"Obesity &Amp; Overweight, Chronic Kidney Disease","enrollment":180},{"nctId":"NCT05726227","phase":"PHASE3","title":"A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2023-07-07","conditions":"Obesity","enrollment":210},{"nctId":"NCT06597019","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-12-09","conditions":"Familial Hypercholesterolemia - Heterozygous","enrollment":51},{"nctId":"NCT07161687","phase":"","title":"A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-10-30","conditions":"Hemophilia A or B","enrollment":50},{"nctId":"NCT06064006","phase":"PHASE2","title":"A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-15","conditions":"Obesity, Overweight","enrollment":125},{"nctId":"NCT05016882","phase":"PHASE2","title":"Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-08-31","conditions":"Non-alcoholic Steatohepatitis","enrollment":698},{"nctId":"NCT06552429","phase":"PHASE2","title":"Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2024-08-29","conditions":"Essential Thrombocythemia","enrollment":27},{"nctId":"NCT05819398","phase":"PHASE2, PHASE3","title":"Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2023-04-17","conditions":"Hidradenitis Suppurativa","enrollment":209}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Depigoid(R)Birch","placebo","Placebo"],"phase":"phase_3","status":"active","brandName":"s.c. injection","genericName":"s.c. injection","companyName":"Leti Pharma GmbH","companyId":"leti-pharma-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"This drug targets the PD-1 receptor to modulate the immune response. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}